Clinical trial
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
NCT00023881 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00023881 |
|---|---|
| Title | Bortezomib in Treating Patients With Chronic Myelogenous Leukemia |
| Official title | Phase II Study of a Proteasome Inhibitor, PS-341 (NSC 681239) in Chronic Myelogenous Leukemia (CML) in Chronic or Accelerated Phase |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 7 |
| Start date | Jul 2, 2001 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 14, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: